136834-22-5

Basic information

• Product Name: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite]
• Synonyms: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite];(2R,3R,4R,5R)-5-(6-Benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluorotetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite;DMT-2'-F-dA(Bz)-CE Phosphoramidite;5'-Dimethoxytrityl-N-Benzoyl-2'-fluoro-3'-[(2-cyanoethyl)-(N,Ndiisopropyl)]-phosphoramidite-deoxyadenosine;N6-Benzoyl-5'-O-(4,4'-Dimethoxy trityl)-2'-deoxy-2'-fluoroadenosine-3'-O-[(2-cyanoethyl)-(N,N-diiso-propyl)]phosphoramidite;5'-DMT-2'-F-Bz-dA Phosphoramidite;Dmt-2'fluoro-da(bz) amidite;2'-F-dA(Bz)-CE Phosphoramidite
• CAS NO: 136834-22-5
• Molecular Formula: C47H51FN7O7P
• Molecular Weight: 875.9227042
• Mol File: 136834-22-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 7.87±0.43(Predicted)
• CAS DataBase Reference: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite](CAS DataBase Reference)
• NIST Chemistry Reference: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite](136834-22-5)
• EPA Substance Registry System: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite](136834-22-5)

Safety Data

• Hazardous Substances Data: 136834-22-5(Hazardous Substances Data)

Usage

Description

N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] is a complex organic compound that is an adenosine derivative. It is characterized by its unique molecular structure, which includes a benzoyl group, a bis(4-methoxyphenyl)phenylmethyl group, and a 2'-deoxy-2'-fluoroadenosine moiety. N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] is synthesized with a 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] group, which is crucial for its applications in the field of molecular biology.

Uses

Used in Pharmaceutical Industry:
N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] is used as a key intermediate in the synthesis of modified nucleotides for improving metabolic stability. The enhanced stability allows these modified nucleotides to be more effective in various biological applications, such as gene silencing and regulation of gene expression.
Used in Biotechnology Industry:
In the biotechnology industry, this adenosine derivative is utilized in the preparation of microRNA inhibitors. MicroRNAs are small, non-coding RNA molecules that play a crucial role in the regulation of gene expression. By inhibiting specific microRNAs, researchers can study their functions and potentially develop novel therapeutic strategies for various diseases.
Used in Chemical Synthesis:
N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] is also used as a building block in the synthesis of more complex molecules with potential applications in various fields, such as pharmaceuticals, agrochemicals, and materials science. Its unique structure and functional groups make it a valuable component in the development of new compounds with specific properties and functions.

Upstream product

• 136834-21-4 N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)3-fluoro-4-hydroxytetrahydrofuran-2-yl)9H-purin-6yl)benzamide triethylammonium salt 
• 79896-97-2 N6-benzoyl-9-β-D-arabinofuranosyladenine 
• 136834-20-3 N-(9-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 136834-18-9 N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine 
• 146954-64-5 N⁶-benzoyl-2'-deoxy-2'-fluoro-3',5'-di-O-tetrahydropyran-2-yladenosine 
• 136834-19-0 N⁶-benzoyl-9-<2-O-(trifluoromethylsulfonyl)-3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl>adenine 
• 102691-36-1 N,N,N',N'-tetraisopropyl 2-cyanoethylphosphorodiamidite 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 98-88-4 benzoyl chloride 
• 124482-92-4 2-cyanoethyl-N,N-(diisopropylamino)chlorophosphine 
• 20187-82-0 2'-fluorodeoxyadenosine 
• 20187-82-0 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine 
• 97614-43-2 1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranose 
• 123318-82-1 clofarabine 

Relevant articles and documents

Cyclic dinucleotide analogues, pharmaceutical composition of analogues and applications of analogues and pharmaceutical composition

The invention discloses cyclic dinucleotide analogues, a pharmaceutical composition of the analogues and applications of the analogues and the pharmaceutical composition. The cyclic dinucleotide analogs (I), an isomer, prodrug, stable isotope derivative or pharmaceutically acceptable salt of the analogs have a structure shown in the specification. The cyclic dinucleotide analogs provided by the invention can be used as regulators of stimulator of interferon genes (STIG) and related signaling pathways, and can effectively treat and/or alleviate multiple types of diseases, including but not limited to malignant tumors, inflammation, autoimmune diseases and infectious diseases; and in addition, the STING regulators can also be used as vaccine adjuvants.

CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS

The present disclosure relates to a compound of formulae (I) or (II), or a pharmaceutically acceptable salt, a solvate, a hydrate thereof, a pharmaceutical composition comprising a compound of formulae (I) or (II), and use thereof, wherein various Markush

Antisense modulation of perilipin expression

Antisense compounds, compositions and methods are provided for modulating the expression of perilipin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding perilipin. Methods of using these compounds for modulation of perilipin expression and for treatment of diseases associated with expression of perilipin are provided.